×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
bluebird bio Reports First Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance
Business Wire
bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today reported first quarter results and business highlights for the...
6 hours ago
Class Action Filed Against bluebird bio, Inc. (BLUE) Seeking Recovery for Investors – Contact Levi & Korsinsky
KXAN Austin
NEW YORK, NY / ACCESSWIRE / May 8, 2024 / If you suffered a loss on your bluebird bio, Inc. (NASDAQ:BLUE) investment and want to learn about...
18 hours ago
First Patient Begins Newly Approved Sickle Cell Gene Therapy
The New York Times
A 12-year-old boy in the Washington, D.C., area faces months of procedures to remedy his disease. “I want to be cured,” he said.
3 days ago
Bluebird Bio Completes First Commercial Cell Collection For LYFGENIA
Contract Pharma
One-time gene therapy for the treatment of sickle cell disease was approved by the FDA in December 2023. bluebird bio Completes First...
3 days ago
ROSEN, A LEADING NATIONAL FIRM, Encourages bluebird bio Inc. Investors to Secure Counsel Before Important ...
KTLA
NEW YORK, May 7, 2024 /PRNewswire/ --. Rosen Law Firm, P.A. Logo. WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers...
1 day ago
Class Action Lawsuit against Bluebird Bio, Inc. (NASDAQ:BLUE) - TipRanks.com
Tipranks
A class action lawsuit was filed against Bluebird Bio, Inc. (NASDAQ:BLUE) on March 28, 2024. The plaintiffs (shareholders) alleged that they...
2 days ago
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in bluebird bio, Inc. with Losses of ...
WATE 6 On Your Side
LOS ANGELES, May 7, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class...
1 day ago
First sickle cell patient begins bluebird gene therapy treatment
The Business Journals
Five months after bluebird bio Inc. won FDA approval for its gene therapy to treat sickle cell disease, the Somerville company said its...
3 days ago
bluebird bio Announces Completion of First Cell Collection for LYFGENIA™ Gene Therapy
Business Wire
bluebird bio, Inc. (Nasdaq: BLUE) announced today that it has completed the first commercial cell collection for LYFGENIA (lovotibeglogene...
3 days ago
Levi & Korsinsky Notifies Shareholders of bluebird bio, Inc.(BLUE) of a Class Action Lawsuit and an Upcoming Deadline
PR Newswire
PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in bluebird bio, Inc. ("bluebird bio" or the "Company") (NASDAQ: BLUE) of a class...
3 days ago